An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1-year, double-blind, randomized trial.
about
Economic considerations in the management of Alzheimer's diseaseCholinesterase inhibitors for Alzheimer's diseaseNon-specialist health worker interventions for the care of mental, neurological and substance-abuse disorders in low- and middle-income countriesLong-Term Cholinesterase Inhibitor Therapy for Alzheimer's Disease: Practical Considerations for the Primary Care PhysicianCost-effectiveness of drug therapies for Alzheimer's disease: A brief review.Treating patients with moderate to severe Alzheimer's disease: implications of recent pharmacologic studies.Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation.Donepezil in Alzheimer's disease: From conventional trials to pharmacogeneticsADCS Prevention Instrument Project: pharmacoeconomics: assessing health-related resource use among healthy elderly.The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease.Donepezil in Alzheimer's disease: an evidence-based review of its impact on clinical and economic outcomes.Pharmacoeconomics of Alzheimer's disease (AD) treatment with cholinesterase inhibitors.High-dose donepezil (23 mg/day) for the treatment of moderate and severe Alzheimer's disease: drug profile and clinical guidelines.Health economic evaluation of treatments for Alzheimer's disease: impact of new diagnostic criteria.Decreased persistence to cholinesterase inhibitor therapy with concomitant use of drugs that can impair cognition.Prevalence, resource utilization and costs of vascular dementia compared to Alzheimer's dementia in a population setting.Disease progression and costs of care in Alzheimer's disease patients treated with donepezil: a longitudinal naturalistic cohort.The role of general practitioners in the diagnosis and treatment of Alzheimer's disease: a multinational survey.Cost-effectiveness of treatments for Alzheimer's dementia.
P2860
Q22241448-9DF3C575-91A3-4A81-AA35-84C0E233882CQ22252975-5B6C14D9-2D7C-493A-A824-995F72021A62Q24202405-4CC5F57F-54DE-4BC5-A450-5D4A157F9A37Q30433785-AC52F618-B6A6-42FE-84F3-3723670AAFA6Q30441091-41EAE649-C9A1-465B-92C9-287F33A3E527Q33928316-5FCC7879-C4ED-4C7B-B836-3AEC32B5AE99Q34153726-0335F834-272D-4EAA-A7A1-27D19AC53FECQ34965949-74890585-04BB-4216-9AA9-54E13C503C9BQ35588243-BCBDEB2A-601F-48FE-9826-28C45E5EFFD4Q35873720-68242159-FC6A-4481-AC30-ED3600D05289Q35876403-7DD2DF10-F392-48B3-9A8D-6738E5B82BFBQ38000091-7A7A414F-2E45-4128-BCED-796E99A33F29Q38086651-D7B6924C-0EEA-4B6B-8581-65D4DC527E65Q39236470-5B148F10-8D06-49EF-A4FF-D3613C2F05A2Q44056102-173854EC-A8CF-43ED-B84C-F005C7CC60A3Q44597506-94CA1B43-8C43-4D1A-B4AB-220EDD643BCFQ45087048-01B48977-938D-49D1-86D0-B41904BF170DQ52001329-28E75A9B-2848-4D22-9C01-9811CDA92A6AQ53310429-1D5A456B-3395-4008-A637-CB59CB4A815D
P2860
An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1-year, double-blind, randomized trial.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
An economic evaluation of done ...... ouble-blind, randomized trial.
@en
An economic evaluation of done ...... ouble-blind, randomized trial.
@nl
type
label
An economic evaluation of done ...... ouble-blind, randomized trial.
@en
An economic evaluation of done ...... ouble-blind, randomized trial.
@nl
prefLabel
An economic evaluation of done ...... ouble-blind, randomized trial.
@en
An economic evaluation of done ...... ouble-blind, randomized trial.
@nl
P2093
P50
P356
P1476
An economic evaluation of done ...... ouble-blind, randomized trial.
@en
P2093
Anders Haglund
Anna-Lena Wetterholm
Donepezil Nordic Study Group
Frans Verhey
Ponni Subbiah
Richard Zhang
Robert Miceli
Vera Mastey
Warren Chin
P356
10.1159/000066669
P577
2003-01-01T00:00:00Z